Entering text into the input field will update the search result below

Unum Therapeutics Files For $86 Million IPO

Mar. 06, 2018 7:31 PM ETUnum Therapeutics (UNUM)1 Comment


  • Unum Therapeutics aims to raise $86.25 million in a U.S. IPO.
  • The firm is in the very early stages of developing immunotherapy drug candidates for the treatment of various cancers.
  • I'll provide a final opinion when we learn more details about the IPO.

Quick Take

Unum Therapeutics (UNUM) intends to sell shares of its common stock for gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.

The firm is a clinical-stage biopharmaceutical company that's focused on the development and commercialization of novel immunotherapy products. Unum’s vision is to provide a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers.

I’ll provide a final opinion when we learn more details such as pricing and valuation assumptions.


Cambridge, MA,-based Unum was founded in 2014. The company has developed an antibody-coupled T-cell receptor (ACTR) platform that causes an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells when combined with tumor-specific antibodies.

Management is headed by CEO Charles Wilson who also founded the company. Prior to Unum, Wilson was the Vice President, Global Head of Strategic Alliances for Novartis (NVS) from 2008-2014 and CTO/Vice President Alliance Management of Archemix from 2001-2008.

The firm’s lead program (based on ACTR technology) is in Phase I clinical testing to assess the safety and efficacy of the product in certain forms of leukemia and lymphoma. Unum’s technology also has the potential to treat many additional types of cancers.

Unum has a number of investors, including Square 1 Bank, New Leaf Venture Partners, Atlas Venture, and F-Prime Capital Partners.


Unum’s goal is to transform cancer treatment through the application of the ACTR platform in a wide range of hematologic and solid tumor cancers. Unum has developed an antibody-coupled T-cell receptor (ACTR platform), a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types.

Unum’s product candidates are comprised of ACTR T-cells co-administered with approved/commercially available antibodies or antibodies in preclinical or clinical development. According to the

An enhanced version of this article including commentary on the IPO is available on my Seeking Alpha Marketplace research service, IPO Edge. I write in-depth research about U.S. IPOs and members learn the latest IPO research, news, market trends and industry analysis. Start with a Free Trial.

This article was written by

Donovan Jones profile picture

Donovan Jones is a research specialist with 15 years of experience identifying opportunities for IPOs and software companies.

He also leads the investing group

IPO Edge

which offers: actionable information on growth stocks through first look S-1 filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.

Learn more


Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

Adam May profile picture
Thanks for the write up! Glad to see Unum already making its way to SA.

News broke (quite possibly after this was submitted for publication) that Unum has had some previously undisclosed patient deaths in the higher dose cohorts for its lead candidate. That will definitely be something to watch out for. Still, I am really excited about the potential of this technology. Combining the adaptability of the CD16 specific NK receptor with the stimulatory domains and cytotoxicity of CD8+ T cells is a brilliant approach. Hoping their pipeline rapidly expands outside of the CD19 space, which is ridiculously crowded.

Thanks again to the author, this is going to be a really fun company to follow!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

More on UNUM

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.